IASP - PAIN 164(2023) 3-13:氨溴索用于神经性疼痛:隐藏在普通的视线?

Ból Pub Date : 2023-10-24 DOI:10.5604/01.3001.0053.9555
Marc A. Russo, Ralf Baron, Anthony H. Dickenson, Kai-Uwe Kern, Danielle M. Santarelli
{"title":"IASP - PAIN 164(2023) 3-13:氨溴索用于神经性疼痛:隐藏在普通的视线?","authors":"Marc A. Russo, Ralf Baron, Anthony H. Dickenson, Kai-Uwe Kern, Danielle M. Santarelli","doi":"10.5604/01.3001.0053.9555","DOIUrl":null,"url":null,"abstract":"Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and local anaesthetic properties. It has a long history of use in the treatment of respiratory tract diseases and has shown to be efficacious in relieving sore throat. In more recent years, ambroxol has gained interest for its potential usefulness in treating neuropathic pain. Research into this area has been slow, despite clear preclinical evidence to support its primary analgesic mechanism of action—blockade of voltage-gated sodium (Nav) channels in sensory neurons. Ambroxol is a commercially available inhibitor of Nav1.8, a crucial player in the pathophysiology of neuropathic pain, and Nav1.7, a particularly exciting target for the treatment of chronic pain. In this review, we discuss the analgesic mechanisms of action of ambroxol, as well as proposed synergistic properties, followed by the preclinical and clinical results of its use in the treatment of persistent pain and neuropathic pain symptoms, including trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome. With its well-established safety profile, extensive preclinical and clinical drug data, and early evidence of clinical effectiveness, ambroxol is an old drug worthy of further investigation for repurposing. As a patent-expired drug, a push is needed to progress the drug to clinical trials for neuropathic pain. We encourage the pharmaceutical industry to look at patented drug formulations and take an active role in bringing an optimized version for neuropathic pain to market.","PeriodicalId":472438,"journal":{"name":"Ból","volume":"30 12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"REPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023) 3–13: Ambroxol for neuropathic pain: hiding in plain sight?\",\"authors\":\"Marc A. Russo, Ralf Baron, Anthony H. Dickenson, Kai-Uwe Kern, Danielle M. Santarelli\",\"doi\":\"10.5604/01.3001.0053.9555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and local anaesthetic properties. It has a long history of use in the treatment of respiratory tract diseases and has shown to be efficacious in relieving sore throat. In more recent years, ambroxol has gained interest for its potential usefulness in treating neuropathic pain. Research into this area has been slow, despite clear preclinical evidence to support its primary analgesic mechanism of action—blockade of voltage-gated sodium (Nav) channels in sensory neurons. Ambroxol is a commercially available inhibitor of Nav1.8, a crucial player in the pathophysiology of neuropathic pain, and Nav1.7, a particularly exciting target for the treatment of chronic pain. In this review, we discuss the analgesic mechanisms of action of ambroxol, as well as proposed synergistic properties, followed by the preclinical and clinical results of its use in the treatment of persistent pain and neuropathic pain symptoms, including trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome. With its well-established safety profile, extensive preclinical and clinical drug data, and early evidence of clinical effectiveness, ambroxol is an old drug worthy of further investigation for repurposing. As a patent-expired drug, a push is needed to progress the drug to clinical trials for neuropathic pain. We encourage the pharmaceutical industry to look at patented drug formulations and take an active role in bringing an optimized version for neuropathic pain to market.\",\"PeriodicalId\":472438,\"journal\":{\"name\":\"Ból\",\"volume\":\"30 12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ból\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5604/01.3001.0053.9555\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ból","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5604/01.3001.0053.9555","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

氨溴索是一种多方面的药物,主要具有黏液活性和分泌作用,同时具有抗炎、抗氧化和局部麻醉特性。它在治疗呼吸道疾病方面有着悠久的历史,并已证明对缓解喉咙痛有效。近年来,氨溴索因其治疗神经性疼痛的潜在用途而引起了人们的兴趣。尽管有明确的临床前证据支持其作用阻断感觉神经元中电压门控钠(Nav)通道的主要镇痛机制,但对这一领域的研究进展缓慢。Ambroxol是一种市售的Nav1.8抑制剂,在神经性疼痛的病理生理学中起着至关重要的作用,而Nav1.7是治疗慢性疼痛的一个特别令人兴奋的靶点。在这篇综述中,我们讨论了氨溴索的镇痛作用机制,以及提出的协同特性,其次是其用于治疗持续性疼痛和神经性疼痛症状的临床前和临床结果,包括三叉神经痛、纤维肌痛和复杂的局部疼痛综合征。氨溴索具有良好的安全性,广泛的临床前和临床药物数据,以及临床有效性的早期证据,是一种值得进一步研究的老药。作为一种专利到期的药物,需要推动该药物进行神经性疼痛的临床试验。我们鼓励制药行业着眼于专利药物配方,并在将神经性疼痛的优化版本推向市场方面发挥积极作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
REPRINTED WITH PERMISSION OF IASP – PAIN 164 (2023) 3–13: Ambroxol for neuropathic pain: hiding in plain sight?
Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and local anaesthetic properties. It has a long history of use in the treatment of respiratory tract diseases and has shown to be efficacious in relieving sore throat. In more recent years, ambroxol has gained interest for its potential usefulness in treating neuropathic pain. Research into this area has been slow, despite clear preclinical evidence to support its primary analgesic mechanism of action—blockade of voltage-gated sodium (Nav) channels in sensory neurons. Ambroxol is a commercially available inhibitor of Nav1.8, a crucial player in the pathophysiology of neuropathic pain, and Nav1.7, a particularly exciting target for the treatment of chronic pain. In this review, we discuss the analgesic mechanisms of action of ambroxol, as well as proposed synergistic properties, followed by the preclinical and clinical results of its use in the treatment of persistent pain and neuropathic pain symptoms, including trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome. With its well-established safety profile, extensive preclinical and clinical drug data, and early evidence of clinical effectiveness, ambroxol is an old drug worthy of further investigation for repurposing. As a patent-expired drug, a push is needed to progress the drug to clinical trials for neuropathic pain. We encourage the pharmaceutical industry to look at patented drug formulations and take an active role in bringing an optimized version for neuropathic pain to market.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信